Grimes & Company, Inc. Incyte Corp Transaction History

Grimes & Company, Inc.

$3.31 Billion
Q2 2024

A detailed history of Grimes & Company, Inc. transactions in Incyte Corp stock. As of the latest transaction made, Grimes & Company, Inc. holds 192,295 shares of INCY stock, worth $13 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares

192,295

Previous 185,093 3.89%

Holding current value

$13 Million

Previous $10.5 Million 10.55%

% of portfolio

0.35%

Previous 0.33%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 22, 2024	BUY	$51.18 - $63.75 $368,598 - $459,127	7,202 Added 3.89%	192,295 $11.7 Million
Q1 2024 Apr 17, 2024	BUY	$56.55 - $66.59 $5 Million - $5.88 Million	88,338 Added 91.3%	185,093 $10.5 Million
Q4 2023 Jan 24, 2024	SELL	$52.16 - $64.19 $4.84 Million - $5.95 Million	-92,723 Reduced 48.94%	96,755 $6.08 Million
Q3 2023 Oct 19, 2023	BUY	$57.77 - $65.93 $148,006 - $168,912	2,562 Added 1.37%	189,478 $10.9 Million
Q2 2023 Jul 19, 2023	BUY	$60.95 - $75.51 $105,138 - $130,254	1,725 Added 0.93%	186,916 $11.6 Million
Q1 2023 Apr 20, 2023	SELL	$70.23 - $86.01 $718,031 - $879,366	-10,224 Reduced 5.23%	185,191 $13.4 Million
Q4 2022 Jan 25, 2023	SELL	$67.18 - $84.11 $493,638 - $618,040	-7,348 Reduced 3.62%	195,415 $0
Q3 2022 Oct 28, 2022	SELL	$66.18 - $82.86 $162,935 - $204,001	-2,462 Reduced 1.2%	202,763 $13.5 Million
Q2 2022 Jul 22, 2022	SELL	$66.18 - $83.18 $131,830 - $165,694	-1,992 Reduced 0.96%	205,225 $15.6 Million
Q1 2022 May 06, 2022	BUY	$66.02 - $79.71 $988,451 - $1.19 Million	14,972 Added 7.79%	207,217 $16.5 Million
Q4 2021 Feb 01, 2022	BUY	$63.34 - $74.11 $94,566 - $110,646	1,493 Added 0.78%	192,245 $14.1 Million
Q3 2021 Nov 08, 2021	BUY	$68.67 - $84.02 $13.1 Million - $16 Million	190,752 New	190,752 $13.1 Million

Others Institutions Holding INCY

# of Institutions

629

Shares Held

198M

Call Options Held

766K

Put Options Held

476K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Grimes & Company, Inc. with notifications on news.

Account

Grimes & Company, Inc. Incyte Corp Transaction History